INmune Bio, Inc.

NasdaqCM INMB

INmune Bio, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -3.20

INmune Bio, Inc. Price to Earnings Ratio (P/E) is -3.20 on January 14, 2025, a 58.58% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

INmune Bio, Inc. 52-week high Price to Earnings Ratio (P/E) is -2.36 on December 20, 2024, which is 26.11% above the current Price to Earnings Ratio (P/E).
INmune Bio, Inc. 52-week low Price to Earnings Ratio (P/E) is -9.17 on February 16, 2024, which is -186.67% below the current Price to Earnings Ratio (P/E).
INmune Bio, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -4.86.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: INMB

INmune Bio, Inc.

CEO	Dr. Raymond Joseph Tesi M.D.
IPO Date	Feb. 4, 2019
Location	United States
Headquarters	225 NE Mizner Boulevard
Employees	11
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Key trends

Past 5 years